CJC-1295 (no DAC), a short-acting GHRH analog, pre-blended with Ipamorelin, a selective ghrelin-receptor agonist, in one vial. The two act on separate pituitary receptors and are studied together for amplified, pulsatile growth-hormone release. Each vial holds 5 mg of each peptide; see the guide for the progressive research schedule.
Mechanism, common research protocols, evidence review, and cited primary literature for CJC-1295 No DAC + Ipamorelin live on the full guide.